VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent eye health company with a market capitalization of $7.1 billion, announced today that its Board of Directors has authorized management to investigate a potential sale of the company. This exploration is part of a broader effort to achieve a complete separation from its parent company, Bausch Health Companies (NYSE:BHC) Inc. According to InvestingPro data, the stock has experienced significant volatility, declining nearly 9% in the past week despite a strong 22% gain over the last six months.
The decision to consider a sale follows a request from the Canadian Investment Regulatory Organization (CIRO), which sought clarification due to market volatility typically associated with such rumors. Bausch + Lomb has confirmed that the process is in progress, but there is no certainty that it will lead to a definitive transaction.
As the company navigates this potential shift, Bausch + Lomb has stated it will not offer additional details until it deems further disclosure is appropriate or necessary. The company's commitment to discretion comes at a time when speculative information can significantly affect stock prices. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with analysts setting price targets ranging from $18 to $26 per share.
Bausch + Lomb, with a history dating back to 1853, has established a substantial global presence, employing approximately 13,000 people across nearly 100 countries. The company generates annual revenue of $4.7 billion with a healthy gross profit margin of 61%. Its diverse product portfolio spans contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter items, and surgical devices. For deeper insights into BLCO's financial health and growth prospects, investors can access comprehensive analysis through InvestingPro, which offers additional ProTips and detailed metrics in its Pro Research Report.
Investors and the market at large are advised to exercise caution regarding forward-looking statements, as actual outcomes may vary based on various risks and uncertainties. Bausch + Lomb has emphasized its responsibility to keep stakeholders informed in accordance with legal requirements and will continue to do so as the situation evolves.
This news is based on a press release statement from Bausch + Lomb and reflects the company's current position on the matter.
In other recent news, Bausch & Lomb Corporation reported a substantial year-over-year increase in third-quarter revenues for 2024, reaching $1.196 billion, primarily driven by products like Miebo and Xiidra, and the contact lens segment, particularly SiHy Dailies. Following these strong results, the company raised its full-year revenue guidance for 2024. The company also secured $400 million in new term loans, providing additional financial flexibility.
In addition to its financial performance, Bausch & Lomb has made strategic moves, acquiring Elios Vision, Inc., a company specializing in a minimally invasive glaucoma surgery procedure. This acquisition is expected to enhance the company's glaucoma treatment portfolio, meeting the growing needs of patients. The ELIOS procedure, already introduced to the European Union market, is currently seeking regulatory approval in the United States.
However, analyst responses to these developments have been mixed. While H.C. Wainwright reaffirmed its Buy rating and upgraded Bausch & Lomb's stock price target to $23.00, both Citi and Morgan Stanley (NYSE:MS) downgraded the company's stock. Stifel maintained a Hold rating with a consistent price target of $19.00. These recent developments underscore the dynamic nature of Bausch & Lomb's operations and its potential for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.